Unternehmen
Gilead Sciences, Inc

Aktueller Kurs
63.33 USD

Symbol
GILD

ISIN
US3755581036

Börse
NASDAQ

Sektor
Health Care

Marktkapitalisierung
79.3861 Mrd. US

Branche
Biotechnology

Dividendenrendite
4.36 %

Ausschüttungsquote
43.87 %

KGV
62.89

KUV (TTM)
3.41

KGVe
9.71

Kursziel
72.46 USD

Unternehmen
Gilead Sciences, Inc

Aktueller Kurs
63.33 USD

Symbol
GILD

ISIN
US3755581036

Börse
NASDAQ

Marktkapitalisierung
79.3861 Mrd. USD

Sektor
Health Care

Branche
Biotechnology

Dividendenrendite
4.36 %

Ausschüttungsquote
43.87 %

KGV
62.89

KUV (TTM)
3.41

KGVe
9.71

Kursziel
72.46 USD

Live-Chart (verzögert)

Firmenbeschreibung

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc Fundamentaldaten

Jahre und Quartale beziehen sich jeweils auf das Geschäftsjahr des Unternehmens. (Das Geschäftsjahr kann ggf. vom Kalenderjahr abweichen.)

Das Geschäftsjahr von Gilead Sciences, Inc endet im Dezember.

Gewinn pro Jahr & Quartal (Net Income) in Mrd. USD

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.000 0.000 0.000 0.000 0.000
2020 1.551 -3.339 0.360 0.000 -1.428
2019 1.975 1.880 -1.165 2.696 5.386
2018 1.538 1.817 2.097 0.003 5.455
2017 2.702 3.073 2.718 -3.865 4.628
2016 3.566 3.497 3.330 3.108 13.501
2015 4.333 4.492 4.600 4.683 18.108
2014 2.227 3.656 2.731 3.487 12.101
2013 0.722 0.773 0.789 0.791 3.075
2012 0.438 0.706 0.676 0.772 2.592
2011 0.651 0.746 0.741 0.665 2.804
2010 0.855 0.712 0.705 0.629 2.901

Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 1.68 1.11 2.11 0 4.9
2019 1.76 1.82 1.75 1.3 6.63
2018 1.48 1.91 1.84 1.44 6.67
2017 2.23 2.56 2.27 1.78 8.84
2016 3.03 3.08 2.75 2.7 11.56
2015 2.94 3.15 3.22 3.32 12.63
2014 1.48 2.36 1.84 2.43 8.11
2013 0.48 0.5 0.52 0.55 2.05
2012 0.46 0.5 0.5 0.5 1.96
2011 0.44 0.5 0.51 0.49 1.94
2010 0.5 0.43 0.45 0.48 1.86

Umsatz pro Jahr & Quartal in Mrd. USD

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 5.548 5.143 6.577 0 17.268
2019 5.281 5.685 5.604 5.879 22.449
2018 5.088 5.648 5.596 5.795 22.127
2017 6.505 7.141 6.512 5.949 26.107
2016 7.794 7.776 7.5 7.32 30.39
2015 7.594 8.244 8.295 8.506 32.639
2014 4.99896 6.53494 6.04183 7.31427 24.89
2013 2.53164 2.76739 2.78283 3.11983 11.2017
2012 2.28245 2.40519 2.4266 2.58828 9.70252
2011 1.92609 2.13725 2.12166 2.20038 8.38538
2010 2.08585 1.92722 1.93766 1.99869 7.94942

Umsatz je Aktie pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 4.37 4.10 5.22 0.00 28.17
2019 4.12 4.45 4.42 4.60 17.58
2018 3.85 4.32 4.28 4.43 16.92
2017 4.93 5.42 4.94 4.51 19.79
2016 5.52 5.74 5.60 5.39 22.38
2015 4.84 5.35 5.52 5.59 21.46
2014 2.98 3.93 3.69 4.44 15.11
2013 1.52 1.63 1.64 1.84 6.61
2012 1.47 1.54 1.53 1.64 6.13
2011 1.19 1.33 1.36 1.39 5.31
2010 1.12 1.07 1.14 1.14 4.55

Gewinn-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -42.47 -315.28 0.00 -100.00 -126.51
2019 65733.33 -4.81 -161.97 0.00 -1.26
2018 0.00 18.14 15.41 -99.86 17.87
2017 -13.06 13.73 -11.55 -242.20 -65.72
2016 -23.85 -1.93 -4.78 -6.67 -25.44
2015 24.27 3.67 2.40 1.80 49.64
2014 181.45 64.12 -25.29 27.66 293.55
2013 -6.51 6.98 2.07 0.36 18.65
2012 -34.22 61.38 -4.33 14.35 -7.56
2011 3.45 14.60 -0.68 -10.25 -3.36
2010 6.57 -16.71 -1.01 -10.71 10.07

Umsatz-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -5.63 -7.30 27.88 0.00 0.00
2019 -8.87 7.65 -1.42 4.91 1.46
2018 -14.47 11.01 -0.92 3.56 -15.24
2017 -11.13 9.78 -8.81 -8.65 -14.09
2016 -8.37 -0.23 -3.55 -2.40 -6.89
2015 3.82 8.56 0.62 2.54 31.13
2014 60.23 30.73 -7.55 21.06 122.20
2013 -2.19 9.31 0.56 12.11 15.45
2012 3.73 5.38 0.89 6.66 15.71
2011 -3.63 10.96 -0.73 3.71 5.48
2010 2.63 -7.60 0.54 3.15 13.38

Gilead Sciences, Inc Fundamentaldaten

Gewinn pro Jahr & Quartal (Net Income)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.000 0.000 0.000 0.000 0.000
2020 1.551 -3.339 0.360 0.000 -1.428
2019 1.975 1.880 -1.165 2.696 5.386
2018 1.538 1.817 2.097 0.003 5.455
2017 2.702 3.073 2.718 -3.865 4.628
2016 3.566 3.497 3.330 3.108 13.501
2015 4.333 4.492 4.600 4.683 18.108
2014 2.227 3.656 2.731 3.487 12.101
2013 0.722 0.773 0.789 0.791 3.075
2012 0.438 0.706 0.676 0.772 2.592
2011 0.651 0.746 0.741 0.665 2.804
2010 0.855 0.712 0.705 0.629 2.901

Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 1.68 1.11 2.11 0 4.9
2019 1.76 1.82 1.75 1.3 6.63
2018 1.48 1.91 1.84 1.44 6.67
2017 2.23 2.56 2.27 1.78 8.84
2016 3.03 3.08 2.75 2.7 11.56
2015 2.94 3.15 3.22 3.32 12.63
2014 1.48 2.36 1.84 2.43 8.11
2013 0.48 0.5 0.52 0.55 2.05
2012 0.46 0.5 0.5 0.5 1.96
2011 0.44 0.5 0.51 0.49 1.94
2010 0.5 0.43 0.45 0.48 1.86

Umsatz pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 5.548 5.143 6.577 0 17.268
2019 5.281 5.685 5.604 5.879 22.449
2018 5.088 5.648 5.596 5.795 22.127
2017 6.505 7.141 6.512 5.949 26.107
2016 7.794 7.776 7.5 7.32 30.39
2015 7.594 8.244 8.295 8.506 32.639
2014 4.99896 6.53494 6.04183 7.31427 24.89
2013 2.53164 2.76739 2.78283 3.11983 11.2017
2012 2.28245 2.40519 2.4266 2.58828 9.70252
2011 1.92609 2.13725 2.12166 2.20038 8.38538
2010 2.08585 1.92722 1.93766 1.99869 7.94942

Umsatz je Aktie pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 4.37 4.10 5.22 0.00 28.17
2019 4.12 4.45 4.42 4.60 17.58
2018 3.85 4.32 4.28 4.43 16.92
2017 4.93 5.42 4.94 4.51 19.79
2016 5.52 5.74 5.60 5.39 22.38
2015 4.84 5.35 5.52 5.59 21.46
2014 2.98 3.93 3.69 4.44 15.11
2013 1.52 1.63 1.64 1.84 6.61
2012 1.47 1.54 1.53 1.64 6.13
2011 1.19 1.33 1.36 1.39 5.31
2010 1.12 1.07 1.14 1.14 4.55

Gewinn-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -42.47 -315.28 0.00 -100.00 -126.51
2019 65733.33 -4.81 -161.97 0.00 -1.26
2018 0.00 18.14 15.41 -99.86 17.87
2017 -13.06 13.73 -11.55 -242.20 -65.72
2016 -23.85 -1.93 -4.78 -6.67 -25.44
2015 24.27 3.67 2.40 1.80 49.64
2014 181.45 64.12 -25.29 27.66 293.55
2013 -6.51 6.98 2.07 0.36 18.65
2012 -34.22 61.38 -4.33 14.35 -7.56
2011 3.45 14.60 -0.68 -10.25 -3.36
2010 6.57 -16.71 -1.01 -10.71 10.07

Umsatz-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -5.63 -7.30 27.88 0.00 0.00
2019 -8.87 7.65 -1.42 4.91 1.46
2018 -14.47 11.01 -0.92 3.56 -15.24
2017 -11.13 9.78 -8.81 -8.65 -14.09
2016 -8.37 -0.23 -3.55 -2.40 -6.89
2015 3.82 8.56 0.62 2.54 31.13
2014 60.23 30.73 -7.55 21.06 122.20
2013 -2.19 9.31 0.56 12.11 15.45
2012 3.73 5.38 0.89 6.66 15.71
2011 -3.63 10.96 -0.73 3.71 5.48
2010 2.63 -7.60 0.54 3.15 13.38

Gilead Sciences, Inc Dividenden-Entwicklung

Ex-Tag Record Date Zahltag Dividende
2020-12-14 2020-12-15 2020-12-30 0.68
2020-09-14 2020-09-15 2020-09-29 0.68
2020-06-11 2020-06-12 2020-06-29 0.68
2020-03-12 2020-03-13 2020-03-30 0.68
2019-12-12 2019-12-13 2019-12-30 0.63
2019-09-12 2019-09-13 2019-09-27 0.63
2019-06-13 2019-06-14 2019-06-27 0.63
2019-03-14 2019-03-15 2019-03-28 0.63
2018-12-13 2018-12-14 2018-12-28 0.57
2018-09-13 2018-09-14 2018-09-27 0.57
2018-06-14 2018-06-15 2018-06-28 0.57
2018-03-15 2018-03-16 2018-03-29 0.57
2017-12-14 2017-12-15 2017-12-28 0.52
2017-09-14 2017-09-15 2017-09-28 0.52
2017-06-14 2017-06-16 2017-06-29 0.52
2017-03-14 2017-03-16 2017-03-30 0.52
2016-12-13 2016-12-15 2016-12-29 0.47
2016-09-14 2016-09-16 2016-09-29 0.47
2016-06-14 2016-06-16 2016-06-29 0.47
2016-03-14 2016-03-16 2016-03-30 0.43